What it sells
Cofactor closes the precision medicine gap with predictive diagnostics
Business model breakdown
Workflow: what inputs become what output?
RNA-seq of FFPE tumor biopsies, a 40-gene machine-learning model (OncoPrism) predicts immunotherapy response ahead of treatment decisions.
Distribution: how it reaches customers
Clinical trial partnerships and health systems; test not yet broadly launched (PREDAPT trial under way).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2015 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.